(NewsDirect)
ECO Animal Health Group PLC CEO DavidHallas joins Proactive's Stephen Gunnion with more on the globalanimal health company focused on pigs and poultry.
Hallas explained the company offers avariety of products aimed at maintaining animal health and treatingdiseases, particularly respiratory and intestinal issues. While asignificant portion of its revenue is attributed to its flagshipproduct, Aivlosin, he said the company maintains a diversifiedportfolio with operations in over 70 countries, more than 20 products,and around 200 licences for different indications.
Hallas highlighted the company'sfourth-quarter and full-year 2024 trading performance, driven byincreasing demand for its products, especially Aivlosin, which assistsin raising healthy animals to meet the global protein demand. Thecompany's growth is notably robust in Brazil, a key proteinproducer.
Hallas clarified that thecompany's operations and revenue are not overly dependent onChina, with over 75% of revenue generated from outside this region.Despite challenges in the Chinese market reported by competitors,Hallas differentiates ECO Animal Health's sector from genetics,emphasizing its focus on animal health and prevention.
Thecompany is also expanding its product line with the upcoming launch ofvaccine products in 2025, following recent trademark approvals in theEU, UK, and the US. Additionally, ECO Animal Health has initiated alimited share buyback, viewing it as an opportunistic use of fundsfollowing property disposals, while still prioritizing investments ininnovation and the current business.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2024 TheNewswire - All rights reserved.